AstraZeneca files suit against Ranbaxy to block generic version of Nexium

Share this article:
AstraZeneca has filed a lawsuit against Ranbaxy Laboratories in an attempt to stop the Indian drug maker from launching a copycat version of its top-selling medicine Nexium (esomeprazole magnesium delayed-release capsules), Reuters reported today.
The lawsuit, filed in U.S. District Court for the District of New Jersey, automatically bars the FDA from approving Ranbaxy's application for 30 months or until an adverse court decision.
"AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting Nexium," the firm said in a statement.
Nexium is AstraZeneca's top-seller, bringing in $3.8 billion in revenue in 2004.
Ranbaxy wants to produce cheap forms of Nexium in 20-and 40-milligram capsule forms.
AstraZeneca is already fighting a challenge to Nexium from Indian generic drug maker Dr. Reddy's Laboratories.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.